Equity Profile

TMDX

TransMedics Group, Inc.

Health CareHealth Care Equipment$2.4B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

TransMedics Group, Inc. Misses on EPS, Stock Down 0.0%

Metric	Actual	Expected	Surprise
EPS	$0.30	$0.61	-51.46%
Revenue	—	$174M	—

management commentary, guidance changes, and full analysis available with Pro.

TransMedics Group, Inc. Misses on EPS, Stock Down 0.0%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.30	$0.61	-51.46%
Revenue	—	$174M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

TransMedics Group, Inc. reported earnings that fell short of expectations, particularly in EPS, which may raise concerns among investors. Despite the miss, the stock reaction was flat, indicating that investors may have anticipated the results. Without any guidance or commentary from management, the outlook remains uncertain.

Company Snapshot

TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$0.61

Revenue

Total revenue reflects the company's ability to generate sales and is critical for assessing growth potential.

$174M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions. Their technology aims to improve the success rates of organ transplants, which is crucial as demand for organ donations continues to rise. With a market cap of $3 billion, they operate in the health care equipment sector, addressing a significant need in patient care.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+101.46%

Avg Stock Reaction

+0.63%

Last Quarter Recap

In the last quarter, TransMedics reported an impressive EPS of $2.62, significantly exceeding expectations. The stock reacted positively, gaining 2.32% the following day.

Management Promises & Guidance

Continued focus on expanding their organ transplant technology.
Commitment to improving patient outcomes through innovative solutions.
Plans to enhance market penetration and customer outreach.

Expectations

Wall Street Expectations

Analysts are generally optimistic about TransMedics' upcoming earnings, expecting solid growth in both EPS and revenue. The company has a strong track record of beating earnings estimates, which adds to positive sentiment.

Bull Case

If TransMedics can deliver an EPS above the consensus and show strong revenue growth, it may reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility.

Key Metrics to Watch

EPS

$0.61

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$174M

Total revenue reflects the company's ability to generate sales and is critical for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.61?

A beat on EPS could signal strong operational performance and boost investor confidence.

What guidance will management provide regarding revenue growth?

Clear guidance on revenue growth will help investors gauge the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth due to new product launches and market expansion strategies that have not been fully accounted for.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger performance than expected.

Recent trends in organ transplant demand suggest a growing market that could drive revenue higher than consensus estimates.

Key Risk

If the company announces a significant new partnership or product that enhances revenue potential, it could shift market expectations dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether TransMedics can sustain its recent growth trajectory, especially after a series of strong earnings surprises.

Bull Confirmed If

An EPS of $0.70 or higher would confirm the bull case, indicating strong demand for their products.

Bear Confirmed If

An EPS below $0.45 would confirm the bear case, suggesting potential issues in sales or cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±15.52%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±15.5% while TMDX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

53.7%

Calls (161K)P/C Ratio: 0.39Puts (64K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TransMedics beats expectations, history suggests the stock could rise by around 0.46%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

Should the company miss expectations, the stock could decline by approximately 0.85%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on market expansion efforts and customer acquisition strategies.
3Insights into operational efficiencies and cost management initiatives.
4Management's outlook on industry trends and demand for organ transplants.
5Guidance on future revenue growth and potential challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$0.61

Revenue

Total revenue reflects the company's ability to generate sales and is critical for assessing growth potential.

$174M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+101.46%

Avg Stock Reaction

+0.63%

Last Quarter Recap

In the last quarter, TransMedics reported an impressive EPS of $2.62, significantly exceeding expectations. The stock reacted positively, gaining 2.32% the following day.

Management Promises & Guidance

Continued focus on expanding their organ transplant technology.
Commitment to improving patient outcomes through innovative solutions.
Plans to enhance market penetration and customer outreach.

Expectations

Wall Street Expectations

Bull Case

If TransMedics can deliver an EPS above the consensus and show strong revenue growth, it may reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility.

Key Metrics to Watch

EPS

$0.61

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$174M

Total revenue reflects the company's ability to generate sales and is critical for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.61?

A beat on EPS could signal strong operational performance and boost investor confidence.

What guidance will management provide regarding revenue growth?

Clear guidance on revenue growth will help investors gauge the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth due to new product launches and market expansion strategies that have not been fully accounted for.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger performance than expected.

Recent trends in organ transplant demand suggest a growing market that could drive revenue higher than consensus estimates.

Key Risk

If the company announces a significant new partnership or product that enhances revenue potential, it could shift market expectations dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether TransMedics can sustain its recent growth trajectory, especially after a series of strong earnings surprises.

Bull Confirmed If

An EPS of $0.70 or higher would confirm the bull case, indicating strong demand for their products.

Bear Confirmed If

An EPS below $0.45 would confirm the bear case, suggesting potential issues in sales or cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±15.52%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±15.5% while TMDX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

53.7%

Calls (161K)P/C Ratio: 0.39Puts (64K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TransMedics beats expectations, history suggests the stock could rise by around 0.46%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

Should the company miss expectations, the stock could decline by approximately 0.85%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on market expansion efforts and customer acquisition strategies.
3Insights into operational efficiencies and cost management initiatives.
4Management's outlook on industry trends and demand for organ transplants.
5Guidance on future revenue growth and potential challenges.